Skip to main content
LIVN
NASDAQ Industrial Applications And Services

LivaNova Reports Strong Q1 Results, Raises Full-Year Guidance, and Secures Key FDA Approval for Sleep Apnea Device

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$57.7
Mkt Cap
$3.15B
52W Low
$35
52W High
$71.92
52W Position info
65% above low
Off High info
20% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

LIVN sits 65% above its 52-week low of $35 on elevated volume (1.8× avg).

Summary

LivaNova PLC reported strong Q1 2026 financial results, raised its full-year revenue and adjusted EPS guidance, and received FDA approval for its aura6000™ System for obstructive sleep apnea.


Key Events · Earnings and Guidance · LIVN

  • Strong First-Quarter 2026 Financial Performance

    LivaNova reported Q1 2026 revenue of $362.3 million, an increase of 14.3% on a reported basis and 11.1% on a constant-currency basis. Adjusted diluted earnings per share rose to $0.98 from $0.88 in the prior-year period.

  • Full-Year 2026 Guidance Raised

    The company raised its full-year 2026 constant-currency revenue growth guidance by 100 basis points to a range of 7.0% to 8.0%. Adjusted diluted EPS guidance was also increased by $0.05 at the midpoint, now expected to be between $4.20 and $4.30.

  • FDA Approval for aura6000™ System

    LivaNova received U.S. FDA premarket approval for its aura6000™ System to treat moderate to severe obstructive sleep apnea. This device is noted as the first and only hypoglossal nerve stimulation system approved without certain contraindications, opening a new high-growth market.


Analysis · LIVN · Industrial Applications And Services

LivaNova PLC delivered robust first-quarter results, exceeding expectations with double-digit revenue growth and improved adjusted earnings per share. The company's decision to raise its full-year 2026 revenue and adjusted EPS guidance signals strong operational momentum and a positive outlook for the remainder of the year. Critically, the FDA premarket approval for the aura6000™ System for obstructive sleep apnea marks a significant product development milestone, positioning LivaNova to enter a high-growth, high-margin market with a differentiated technology. This combination of strong financial performance, an upgraded outlook, and a major regulatory approval provides a compelling positive catalyst for the company's trajectory.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 51.2% of the 201 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LIVN was trading at $57.70 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $35.00 to $71.92. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LIVN - Latest Insights

LIVN
Nov 04, 2026, 3:02 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $96.42
Real-time Price: $91.14 info
Change: -$5.28 (-5%) info
Market Cap: $5.021B info
LIVN
Nov 04, 2026, 6:02 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $79.90
Real-time Price: $91.14 info
Change: +$11.24 (+14%) info
Market Cap: $5.021B info
LIVN
Nov 04, 2026, 6:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $79.90
Real-time Price: $91.14 info
Change: +$11.24 (+14%) info
Market Cap: $5.021B info
LIVN
Aug 06, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $78.15
Real-time Price: $91.14 info
Change: +$13.00 (+17%) info
Market Cap: $5.021B info
LIVN
Aug 05, 2026, 2:23 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $76.37
Real-time Price: $91.14 info
Change: +$14.77 (+19%) info
Market Cap: $5.021B info